WallStreetZenWallStreetZen

NASDAQ: SYRE
Spyre Therapeutics Inc Stock Ownership - Who owns Spyre Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Spyre Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Cameron TurtleChief Executive Officer2025-12-0110,995$28.73
$315.89kSell
Cameron TurtleChief Executive Officer2025-12-014,005$29.83
$119.47kSell
Cameron TurtleChief Executive Officer2025-11-0328,155$23.13
$651.23kSell
Cameron TurtleChief Executive Officer2025-11-0316,845$23.66
$398.55kSell
Scott L. BurrowsChief Financial Officer2025-09-0218,428$16.26
$299.64kSell

1 of 1

SYRE insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when SYRE insiders and whales buy or sell their stock.

SYRE Shareholders

What type of owners hold Spyre Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Fairmount Funds Management LLC18.43%14,301,760$495.70MInsider
Fmr LLC11.68%9,060,144$314.02MInstitution
Fairmount Funds Management LLC5.18%4,018,101$139.27MInstitution
Blackrock Inc5.13%3,982,744$138.04MInstitution
Rtw Investments LP4.67%3,621,996$125.54MInstitution
Tang Capital Management LLC4.12%3,200,000$110.91MInstitution
Baker Bros Advisors LP3.99%3,094,590$107.26MInsider
Vanguard Group Inc3.93%3,050,730$105.74MInstitution
Orbimed Advisors LLC3.65%2,829,748$98.08MInsider
Vr Adviser LLC3.46%2,685,448$93.08MInstitution

1 of 3

SYRE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
SYRE71.39%28.61%Net SellingNet Selling
SLNO35.66%64.34%Net Selling
RCUS64.05%35.95%Net BuyingNet Selling
AAPG0.03%0.00%
DYN83.29%16.71%Net BuyingNet Selling
View Top Biotech Stocks

Spyre Therapeutics Stock Ownership FAQ

Who owns Spyre Therapeutics?

Spyre Therapeutics (NASDAQ: SYRE) is owned by 82.87% institutional shareholders, 33.21% Spyre Therapeutics insiders, and 0.00% retail investors. Fairmount Funds Management LLC is the largest individual Spyre Therapeutics shareholder, owning 14.30M shares representing 18.43% of the company. Fairmount Funds Management LLC's Spyre Therapeutics shares are currently valued at $491.41M.

If you're new to stock investing, here's how to buy Spyre Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.